 |
 |
> http://www.webmd.com/parkinsons-disease/news/20090923/can-early-treatment-a >zilect-slow-parkinsons I wonder how these studies can be impartial: Teva supported the ADAGIO study. Olanow and colleagues reported relationships with Teva, Lundbeck, Boehringer Ingelheim, Novartis/Orion, Solvay, Ceregene, Merck Serono, Ceregene, Eisai, Eutherapie, GlaxoSmithKline, Osmotica, Schering-Plough, Pierre Fabre, Allergan Neuroscience, Alphamedica, ApotheCom, Axis Healthcare, Bayer Schering, CNS Schering-Plough, Centopharm, Embryon, Genzyme, Impax, Ipsen, Kyowa, Merck, Ortho-McNeil, Pfizer, Prestwick, Quintiles, Santhera, Schwarz Pharma, Valeant Pharm, Vernalis, Acadia, SkyePharma, UCB Pharma, INC Research, Mentor, Asubio, i3 Research, Chelsea Therapeutics, Advanced Neuromodulation Systems, Medtronic Neurological, Neurogen, and Orion. D'Agostino reported being a special employee of the FDA, but had no relationships with industry. Lewitt reported relationships with Allergan, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, Schwarz Pharma (now UCB), Solstice, Vernalis, Asubio, Brittania, Eisai, Impax, Kyowa, Neurim, Neuroderm, Neurologix, Orion, Prestwick, Spherics, XenoPort, Merck & Co., Santhera, Schering-Plough, Supernus, Valeant, and Chelsea Therapeutics. Wojcieszek reported a relationship with Teva. Ahlskog reported no potential conflicts. Weiner reported relationships with Teva, Boehringer Ingelheim, Santhera, Biogen Idec, and Novartis. Kremens reported a relationship with Teva. maryse ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn